1y return+42.1%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2023: $147 against $157 in the S&P 500.2
Atle Fund Management ABS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| LLYEli Lilly & Co | $35.8M | 9.6% | −24.9% |
| MRKMerck & Co. Inc | $24.3M | 6.5% | +459.4% |
| JNJJohnson & Johnson | $21.7M | 5.8% | −7.5% |
| ABBVAbbvie Inc | $16.2M | 4.4% | −40.5% |
| CVSCvs Health Corp | $15.1M | 4.1% | +514.6% |
| TMOThermo Fisher Scientific Corp | $14.0M | 3.8% | +21.2% |
| RVMDRevolution Medicines Inc | $13.7M | 3.7% | −88.2% |
| BIIBBiogen Inc | $13.6M | 3.6% | New |
| NBIXNeurocrine Biosciences Inc | $12.3M | 3.3% | −18.7% |
| MIRMMirum Pharmaceuticals Inc | $11.8M | 3.2% | −48.5% |
| Alkermes PLCCUSIP G01767105 | $11.2M | 3.0% | −12.0% |
| IONSIonis Pharmaceuticals Inc | $10.9M | 2.9% | +392.0% |
| ONCBeone Medicines Ltd-adr | $10.0M | 2.7% | −15.7% |
| ISRGIntuitive Surgical Inc | $9.8M | 2.6% | −65.2% |
| SYKStryker Corporation | $9.5M | 2.6% | +12.8% |
| VRTXVertex Pharmaceuticals Inc | $9.5M | 2.6% | −16.8% |
| EWEdwards Lifesciences Corp | $9.3M | 2.5% | −3.1% |
| BBIOBridgebio Pharma Inc | $9.3M | 2.5% | +12.0% |
| KRYSKrystal Biotech, Inc | $8.9M | 2.4% | −36.1% |
| CORCencora Inc | $8.8M | 2.4% | +32.6% |
| Newamsterdam Pharma Co NvCUSIP N62509109 | $8.4M | 2.3% | +162.5% |
| ABVXAbivax Sa | $7.8M | 2.1% | +84.1% |
| INCYIncyte Corp | $6.5M | 1.7% | +12.1% |
| IRTCIrhythm Technologies Inc | $6.4M | 1.7% | +142.4% |
| BSXBoston Scientifc | $6.2M | 1.7% | +262.0% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| MIRMMirum Pharmaceuticals Inc | March 31, 2024 | +366.0% | $11.8M |
| RVMDRevolution Medicines Inc | December 31, 2024 | +328.2% | $13.7M |
| KRYSKrystal Biotech, Inc | December 31, 2023 | +199.6% | $8.9M |
| PYXSPyxis Oncology Inc | December 31, 2025 | +161.7% | $2.9M |
| CAHCardinal Health Inc | December 31, 2023 | +135.7% | $5.6M |
| BCAXBicara Therapeutics Inc | March 31, 2025 | +127.9% | $4.3M |
| Alkermes PLCCUSIP G01767105 | June 30, 2024 | +117.4% | $11.2M |
| CELCCelcuity Inc | September 30, 2025 | +111.8% | $3.5M |
| LLYEli Lilly & Co | December 31, 2023 | +105.8% | $35.8M |
| BBIOBridgebio Pharma Inc | December 31, 2023 | +84.5% | $9.3M |
Sold off last quarter
- AMGNAmgen Inc was $8.7M
- UNHUniversal Health Services Inc was $2.8M
- Soleno Therapeutics IncCUSIP 834203309 was $2.2M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +22.2% | +14.8% |
| March 31, 2026 | −4.5% | −4.6% |
| December 31, 2025 | +14.6% | +2.4% |
| September 30, 2025 | +6.2% | +7.8% |
| June 30, 2025 | −2.5% | +10.5% |
| March 31, 2025 | +5.1% | −4.6% |
| December 31, 2024 | −8.2% | +2.1% |
| September 30, 2024 | +1.5% | +5.4% |
| June 30, 2024 | −2.6% | +4.0% |
| March 31, 2024 | +11.0% | +10.0% |
| March 31, 2023 | −4.0% | +7.0% |
| December 31, 2022 | +15.4% | +7.1% |
| September 30, 2022 | +1.1% | −5.3% |
| June 30, 2022 | −1.5% | −16.5% |
| March 31, 2022 | +8.6% | −4.9% |
| December 31, 2021 | −3.7% | +10.7% |
| September 30, 2021 | −7.7% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Atle Fund Management AB Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1381843&type=13F-HR&dateb=&owner=include&count=40CIK 1381843
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1381843/000138184326000005/Filed July 24, 2026 · accession 0001381843-26-000005